Home › NDC Lookup › RxCUI directory › RxCUI 2044932

Fostamatinib 150 MG Oral Tablet [Tavalisse] — RxCUI 2044932

RxNorm drug concept · Semantic branded drug
RxCUI 2044932 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2044932
Official nameFostamatinib 150 MG Oral Tablet [Tavalisse]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTavalisse 150 MG Oral Tablet; Tavalisse 150 MG (equivalent to 189.3 MG fostamatinib disodium) Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)407 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fostamatinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tavalisse is used to treat a condition called chronic immune thrombocytopenia, or ITP — where your immune system mistakenly destroys your platelets, the blood cells that help you c...
  • What exactly is this medication for, and why was I prescribed it?
  • Good news — you can take Tavalisse with or without food, so there's no strict meal requirement. If you miss a dose, just skip it and take your next one at the normal time. Don't ta...
  • Can I take this with food, and what should I do if I miss a dose?
📖 Read our full Fostamatinib guide →

🕸️ Concept Web — How Fostamatinib 150 MG Oral Tablet [Tavalisse] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Fostamatinib 150 MG Oral Tablet [Tavalisse] RxCUI 2044932

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Fostamatinib 2044896
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tavalisse 2044923
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fostamatinib Oral Tablet 2044921
    • Fostamatinib Oral Product 2044919
    • Fostamatinib Pill 2044920
    • Fostamatinib Oral Tablet [Tavalisse] 2044925
    • Tavalisse Oral Product 2044926
    • Tavalisse Pill 2044927
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fostamatinib 150 MG Oral Tablet SCD · 2044930
  • Fostamatinib 150 MG SCDC · 2044929
  • Fostamatinib Oral Tablet SCDF · 2044921
  • Fostamatinib Oral Product SCDG · 2044919
  • Fostamatinib Pill SCDG · 2044920

Brand-Name Concepts

  • Fostamatinib 150 MG [Tavalisse] SBDC · 2044931
  • Fostamatinib Oral Tablet [Tavalisse] SBDF · 2044925
  • Tavalisse Oral Product SBDG · 2044926
  • Tavalisse Pill SBDG · 2044927
  • Tavalisse BN · 2044923

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2044932 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71332-0001-01 60 TABLET in 1 BOTTLE (71332-001-01) TAVALISSE Rigel Pharmaceuticals, Inc. 2018-05-09
71332-0002-01 60 TABLET in 1 BOTTLE (71332-002-01) TAVALISSE Rigel Pharmaceuticals, Inc. 2018-05-09
Observed labelers: Rigel Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.